PreprintReviewVersion 1This version is not peer-reviewed
Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study
Version 1
: Received: 27 August 2024 / Approved: 28 August 2024 / Online: 28 August 2024 (13:41:36 CEST)
How to cite:
Kapsali, I.; Brinia, M.-E.; Constantinides, V. C. Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study. Preprints2024, 2024082030. https://doi.org/10.20944/preprints202408.2030.v1
Kapsali, I.; Brinia, M.-E.; Constantinides, V. C. Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study. Preprints 2024, 2024082030. https://doi.org/10.20944/preprints202408.2030.v1
Kapsali, I.; Brinia, M.-E.; Constantinides, V. C. Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study. Preprints2024, 2024082030. https://doi.org/10.20944/preprints202408.2030.v1
APA Style
Kapsali, I., Brinia, M. E., & Constantinides, V. C. (2024). Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study. Preprints. https://doi.org/10.20944/preprints202408.2030.v1
Chicago/Turabian Style
Kapsali, I., Maria-Evgenia Brinia and Vasilios C. Constantinides. 2024 "Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-synuclein in Parkinson’s Disease. A Systematic Review, Meta-Analysis and Meta-Regression Study" Preprints. https://doi.org/10.20944/preprints202408.2030.v1
Abstract
Background: Diagnostic accuracy of Parkinson’s disease (PD), a synucleinopathy, based on diagnostic criteria is suboptimal. A biomarker for synucleinopathies is pivotal both from a clinical and from a research aspect. CSF a-synuclein has been extensively studied over the past two decades as a candidate biomarker of synucleinopathies. Herein we present data on studies focusing on total, phosphorylated and oligomeric CSF a-synuclein in PD. Methods: Pubmed, Scopus and Web of Science were searched for studies with >10 PD patients and control subjects, with data (mean, SD) on total, phosphorylated or oligomeric a-synuclein. Cohen’s d, as a measure of effect size, was calculated for all a-synuclein forms. Subgroup analysis and meta-regression were performed in an effort to explain between-study heterogeneity. Results: Thirty studies on total, six studies on oligomeric and one study on phosphorylated a-synuclein were included. Total a-synuclein was decreased and oligomeric a-synuclein increased in PD patients vs. controls. Effect size was medium for total and high for oligomeric a-synuclein. A-syn forms provided suboptimal combined sensitivity/specificity for the differentiation of PD from controls. There was significant between-study heterogeneity. PD cohort characteristics (sex, age, disease duration, UPDRS, H&Y) and study characteristics (study design, healthy vs. neurological controls, control for CSF blood contamination, method of a-syn measurement) could not account for between-study heterogeneity. Publication bias was limited. Conclusions: CSF a-synuclein levels lack sufficient accuracy to be used as biomarkers for PD. Standardization of (pre)analytical variables may improve the discriminatory power of a-synuclein forms in the future.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
